Supplementary Figure S1 (Mishra et al) MDA-MB-231 Time (min) 0 30 45 90 180 240 Sema 3A - + + + + + (100 ng/ml) Foxo 3a Free probe 1 2 3 4 5 6 b Foxo 3a.

Slides:

Advertisements

Similar presentations

Classroom Bill of Rights

Advertisements

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Tumour TypeClassificationCell LineCell Line OriginID Testing Method Date ID Test (month-year). Prostate LNCaPATCC CRL 1740STR AnalysisAug-11 Breast BT-474cDrs.J.

Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.

(+++) Normal breast ATM (++) IDC ATM Lymph node metastasis negative positive P-value A B X200 C Vector ATM - WT.

Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.

Figure S1. RNA-seq results for caveolin-1 (Cav1). Upper panel: UCSC genome browser view. Lower panel: quantification o f Cav1 expression based on RNA-seq.

Introduction into trigonometry Born: 190 BC in Nicaea, Bithynia (now Turkey) Died: 120 BC in probably Rhodes, Greece Hipparchus of Rhodes Hipparchus Compiled.

Journal title: Autophagy Induction by Capsaicin in Malignant Human Breast Cells is Modulated by p38 and ERK Mitogen-Activated Protein Kinases and Retards.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

Nardella et al. Supplementary Fig. 1 Murine Rheb wt Line 47 Line 50 Log gene expression (a.u.) ******* 200 bp Founders

MDA-MB h MDA-MB h a MDA-MB h MDA-MB-468 MDA-MB h MDA-MB h MCF-7 48h MCF-7 72h b c ef g h MDA-MB h clomipramine.

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -

Figure S1. Zhao et al. a b c Figure. S1. VEGF does not stimulate population increase and cell cycle changes in breast cancer cells. (a) cells from.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Wu et al., Supplementary Fig 1 Supplementary Figure 1: The depletion of BRG1 in HeLa cells has no effect on cell proliferation. Sh- empty vector was used.

PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K/Akt/GSK-3β/GATA-6 signaling pathways in TNF-α-activated human endothelial.

Lung squamous cell carcinoma

Standard Form A number expressed in standard form is a number written between 1 and 10 multiplied by 10 to an appropriate power. The use of standard form.

Hallett, et al., - Supplementary Figure 1

Volume 18, Issue 6, Pages (December 2010)

Supplementary Figure S1.

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/ M

Plenary: rules of indices

KG-501 suppresses NSCLC/IL-1β CM–induced migration of HUVECs by regulating IL-1β–induced CXC chemokine gene expression in NSCLC cells. KG-501 suppresses.

IL-1β significantly augments the angiogenic activity of NSCLC by inducing the expression of angiogenic CXC chemokine genes. IL-1β significantly augments.

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression.

FP1 Matrices Introduction

سرطان الثدي Breast Cancer

Nor Supp.Fig. S1 Raja et al. a b c d e f 1 2 Hyp - + Hyp - +

A B C Supplementary Figure 1 Group 1 Group 2 Group 3 #1 #2 #3 #4 #5 #6

Nat. Rev. Clin. Oncol. doi: /nrclinonc

ОПШТИНА КУРШУМЛИЈА.

Figure 2 The association between CD8+ T‑cell density of the tumour

Triple‐negative breast cancer (TNBC) cells in human express a specific gene signature and their self‐renewal depends on canonical Wnt/β‐catenin signalling.A.Human.

RIDD of miRNA (miRIDD) signals in GBM

Volume 18, Issue 6, Pages (December 2010)

Cetuximab treatment increases IFNγ receptor 1 expression.

relative to untreated vector

Sequencing at 10,000x using Illumina paired reads

Index Notation Sunday, 24 February 2019.

Volume 14, Issue 8, Pages (March 2016)

HeLa COS-7 Supplementary Figure S1 Coelho et al (2014) MM pSPL3 MM

Roth et al, Supplementary Figure 1

Table S1: Characteristics of the cancer patients

(apoptotic + necrotic)

Pten deficiency induces strong stromal reaction with immune cell infiltration and promotes the development of invasive and metastatic pancreatic tumors.

Supplementary Fig S1, Zembutsu H et al.

UCN‐01 inhibits FoxO3 inactivation in human lung fibroblasts stimulated with growth factors UCN‐01 inhibits FoxO3 inactivation in human lung fibroblasts.

TGF-β stimulates SMAD7 expression via FOXO3.

Review Summary 29 elements achieved by courses

© The Author(s) Published by Science and Education Publishing.

Biphasic increase of PI(4,5)P2 level in LPS-stimulated cells.

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

HIF-1 is required for IGF-1-induced VEGF mRNA expression and protein secretion. HIF-1 is required for IGF-1-induced VEGF mRNA expression and protein secretion.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

Activation of membrane-associated Akt is associated with loss of apoptosis in TgAPT121;Pten+/− prostates. Activation of membrane-associated Akt is associated.

Changes in signal transduction pathway induced by gefitinib.

Correlations of the breast cancer hypoxia metagene with Ki67 and the proliferation metagene. Correlations of the breast cancer hypoxia metagene with Ki67.

Transcriptional activity and growth of mutant ER in a breast cancer cell line. Transcriptional activity and growth of mutant ER in a breast cancer cell.

Fig. 3. PTEN a target of miR-182-5p

PTEN-deficient prostate cancer cells exhibit constitutive macropinocytosis. PTEN-deficient prostate cancer cells exhibit constitutive macropinocytosis.

8 Core Steps of success: I.Step:1 : DREAM SETTING: II. Step: 2 : LIST MAKING : IV. Step: 4 : SHOW THE PLAN: III. Step: 3 : INVITATION: V. Step: 5 : FOLLOW.

Expression of anti-versican shRNA decreased breast cancer cell mammosphere and colony formation. Expression of anti-versican shRNA decreased breast cancer.

U A B II III I IV 94.

Presentation transcript:

Supplementary Figure S1 (Mishra et al) MDA-MB-231 Time (min) Sema 3A (100 ng/ml) Foxo 3a Free probe b Foxo 3a Free probe MDA-MB Sema 3A (100 ng/ml) Coni PTENi dnPTEN wt PTEN d Sema 3A (100 ng/ml) Coni NRP1i NRP1 neu Ab (5µg/ml) NRP1 block pep (20 µg/ml) Foxo 3a Free probe MDA-MB-231 c Time (min) Sema 3A (100 ng/ml) MDA-MB Akt Mw (kDa) pAkt a Cold Probe-1 (25X) Foxo 3a Free probe MDA-MB-231 FP Wt Probe-1 FP Mut Probe-2 e

Control Coni Sema 3A Sema A + PTENi Sema 3A + dn PTEN Sema 3A + wt PTEN MDA-MB h 16 h b MDA-MB-231 a a Control Coni b c Sema 3A Sema 3A + wt PTEN d Sema 3A + PTENi e f Sema 3A + dn PTEN Supplementary Figure S2 (Mishra et al)

b Control Coni Sema 3A Sema 3A+ wt Foxo 3a Sema 3A + Foxo 3ai Sema 3A + Foxo 3a TM MDA-MB h 16 h Supplementary Figure S3 (Mishra et al) a ab c d e f Control Coni Sema 3A Sema 3A + wt Foxo 3a Sema 3A + Foxo 3ai Sema 3A + Foxo 3a TM MDA-MB-231

Supplementary Figure S4 (Mishra et al) a MDA-MB-231 Control a b Coni Sema 3A c Sema 3A + NRP1i d Sema 3A + NRP1 neu Ab e Sema 3A + NRP1 block pep f ControlConi 0 h Sema 3A Sema 3A + NRP1i Sema 3A+ NRP1 neu Ab Sema 3A + NRP1 block pep 16 h MDA-MB-231 b

Co-migration HUVEC (Upper chamber) Coni Medium rhSema 3ArhSema 3A + NRP-1i rhSema 3A + NRP-1 neu Ab CM MDA-MB-231 cells (Lower chamber) Co-invasion a b c d e a b cd e I II b Supplementary Figure S5 (Mishra et al) ConiMedium NRP1i NRP1 neu Ab NRP1 block pep Co-migration HUVEC (Upper chamber) a c e f Co-invasion CM MDA-MB-231 cells (Lower chamber) a b c d e f b d a I II HUVEC Medium Coni CM MDA-MB rh Sema 3A (Lower chamber) NRP-1 neu Ab NRP-1i migration/invasion (% Control) ** * * # ## CM MDA-MB rh Sema 3A c

b MDA-MB-231 MDA-MB-231- Sema 3A 0 h 16 h Supplementary Figure S6 (Mishra et al) 0 h 24 h MCF-7 Control Sema 3A block pep (20μg/ml) c a b MDA-MB-231 MDA-MB-231- Sema 3A a

a rhVEGF + NRP1 neu Ab rhVEGF + rhSema 3A + NRP1 neu Ab rhVEGF + CM MDA-MB-231 -Sema 3A Medium a rhVEGF b rhSema 3A c rhVEGF + rhSema 3A d e g f b Tube length (% Control) * ** VEGF (50 ng/ml) Medium NRP1 neu Ab (5 µg/ml) Sema 3A (100 ng/ml) CM MDA-MB-231-Sema 3A Medium rhVEGF rhSema 3A rhVEGF + rhSema 3A 0 h 48 h a b c d ef g h c Change in length and size * ** Medium rhVEGF rhSema 3A rhVEGF + rhSema 3A d Supplementary Figure S7 (Mishra et al)

Supplementary Figure S8 (Mishra et al) d Ki67 i ii CD31/DAPI iii iv VEGF MCF-7- Sema 3A block pep MCF-7 vi v pFoxo 3a MCF-7-Sema 3A shRNA MCF-7-mock vector a MCF-7-Sema 3A block pep (1 mg/Kg body weight) MCF-7 b MCF-7- Sema 3A block pep MCF-7 MelCAM ixx Sema 3A c i ii pPTEN iii iv Foxo 3a vii viii v vi Probability FOXO3A Relapse free survival (years) n=2878 e

Test Statistics a Sema 3A ExpressionpPTEN Expression Mann-Whitney U.000 Wilcoxon W Z Asymp. Sig. (2-tailed).317 Exact Sig. [2*(1-tailed Sig.)] b a. Grouping Variable: SrNo b. Not corrected for ties. Correlation between Sema 3A & pPTEN with breast cancer progression Supplementary Table S1 (Mishra et al )